
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. reported a significant year-over-year revenue increase, with Cell Processing revenue reaching $25.3 million, reflecting a growth of 33%, and total revenue for 3Q25 at $28.1 million, which is a 31% year-over-year growth and exceeding projections. The company also achieved a net income of $0.6 million, or $0.01 per share, contrasting sharply with prior estimates of a net loss, which indicates improved profitability. Furthermore, BioLife Solutions is positioned for continued growth with expectations of gross margins in the low-60% range and a reduction in net losses, supported by a strong cash position and the anticipated benefits from their Center for biopreservation and cell processing innovations.
Bears say
The financial outlook for BioLife Solutions Inc. is hindered by several significant risks, including the potential for lower-than-anticipated growth of its products and services and difficulties in acquiring new customers. Additionally, revenue guidance for FY2025 was adjusted downward by approximately $8 million, indicating expectations for only 27-29% year-over-year growth, predominantly driven by its Cell Processing platform. Furthermore, the company faces challenges such as fluctuations in foreign exchange rates and potential dilution, which could negatively impact its financial stability and long-term growth prospects.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares